



Bill Harriman, PhD  
SVP Antibody Discovery

# SVP Antibody Discovery

October 18, 2022

# The OmniAb Technology Suite


## OmniAb<sup>®</sup>




Ab Initio  
Biotherapeutics

See Dev's poster  
#51

xCella  
BIOSCIENCES



ICAGEN<sup>®</sup>  
ION CHANNEL TECHNOLOGY



At OmniAb  
booth

The only platform  
leveraging **four species**

Robust solutions for  
**bispecific antibodies**

Human frameworks with  
**ultralong CDR-H3s**


Industry-leading  
**broadest offering**

**Proven success**

# Platforms to Generate Custom Antibody Repertoires

BIOLOGICAL INTELLIGENCE™: INTERPLAY BETWEEN RATIONAL GENETIC DESIGN AND POWERFUL IN VIVO PROCESSES


Naïve repertoire



## Building the Animal System


- V gene building blocks
- Structural attributes
- Diversification architecture
- Transgene design
- Immunological robustness

Immune repertoire



## Repertoire Shaping

- Antigen design
- Host immune recognition
- Immunization protocols
- Campaign strategy
- Immune response monitoring




## Repertoire Mining

- Phenotypic screening
- Clonal sampling/sequencing
- Antibody characterization
- Clone & Repertoire ranking
- Selective "Deep Dives"
- NGS hit expansion


# OmniAb Program Count Continues to Grow

PROGRESSION AND PERFORMANCE IN PROGRAMS BY STAGE OF DEVELOPMENT

As of 2016



As of 09/30/22



Substantial progress in all phases, increase in discovery programs expected to feed growth in new clinical programs and future approvals



# Animal Platforms


---




# Rodent Platforms

- Endogenous Ig genes inactivated
- Expression of full human V gene diversity
- Streamlined conversion into fully human molecule

Well-validated transgene design utilizes rodent constant regions for robust immune responses from the B-cell repertoire





Greater evolutionary distance yields greater immunogenicity and more antibody diversity




# Engineering of Ig Loci

ADAPTATION TO CHICKEN GENE CONVERSION PROCESS

OmniChicken®


## Gene conversion



## Human V's selected for:


- High expression level, stability, ubiquity
- High sequence diversity in CDRs
- Low sequence diversity in FWs

## Engineered locus



*Gene conversion*


## Diversified B-cells






# Common Light Chain Platforms

STANDARD IGG FORMAT TO DE-RISK DOWNSTREAM DEVELOPMENT<sup>†</sup> OF BISPECIFIC MABS



Rearranged human VK3-15 light chain combined with diversifying heavy chain



Simple reformatting from monospecific into bispecific for efficient production



Bispecific IgG



"Germlining" human VK3-15 light chain combined with diversifying heavy chain




Monospecific IgG

Common light chain for OmniFlic<sup>®</sup> and OmniClic<sup>®</sup> allows interchangeability between the platforms

<sup>†</sup>The Evolution of Bispecific Antibodies, Nimish Gera  
<https://doi.org/10.1080/14712598.2022.2040987>

# OmnidAb™: Heavy Chain Only Transgenic Chickens

HCO STRATEGY USING TRUNCATED LIGHT CHAIN (TLC)




- Normal chicken heavy chain can express as VH alone
- VHH transgene in development

# OmniTaur™: Ultralong CDRH3s Create Novel Binding Domains




11

## UNIQUE STRUCTURAL FEATURES OF ULTRALONG H3 ANTIBODIES



- Novel structure may enable targeting epitopes unreachable by standard antibodies
- Long H3 domains can be expressed on human VH framework, or alone as ~5kD Picobodies™




Stanfield, et.al. *Sci Adv* (2020) 6(20): eaba0468.



# OmniTaur™ mAbs Share a Structural Theme with Bioactive Natural Peptides



Shk peptide




Cow antibody "knob"




Long H3 mAbs potentially combine high biological potency with high target specificity

# mAb Binding Modes to Ion Channel Kv1.3

H3 LENGTH IMPACTS TYPES OF MOLECULAR INTERACTION










Long H3 mAb binds within pore



Nanobodies (~15KD) bind turret loops

# OmniAb Antibody Repertoires

UNSURPASSED OPTIONS AVAILABLE TO ADDRESS DIVERSE PARTNER OBJECTIVES

Host	V genes	Structural and immunological features	Benefits for therapeutics discovery and development
	Full human V gene diversity Choice of light chain isotype	Diverse V gene usage and mixed genetic backgrounds	Widely accessible and flexible workflows
	Full human V gene diversity Choice of light chain isotype	Diverse V gene usage and mixed genetic backgrounds Distinctive target recognition	Industry standard Widely accessible and flexible workflows Extensive track record
	Single framework VH3/VK3 or VH3/VL1	Evolutionarily divergent host system for robust immune responses	Diverse and new epitope coverage High homology targets Excellent physical properties
	Full human VH gene diversity with non-diversifying VK3	Fixed light chain for bispecific applications	Bispecific applications leveraging standard IgG format
	Single framework VH3/non-diversifying VK3	Fixed light chain for bispecific applications	Diverse epitope coverage Excellent physical properties Ease of manufacturing
	Single camelized human VH framework with truncated LC	Domain antibody of the "VHH" type	Diverse and new epitope coverage from human single-domain format, 12-15kD Building blocks for multispecific molecules
	Single framework VH4/VL1	Ultralong CDR-H3's for enormous structural diversity	Access cryptic epitopes Unique modalities (picobodies™) Building blocks for multispecific molecules



# Screening Platforms


---





# Discovery Platforms

16




Our powerful single B-cell screening technologies, **xPloration®** and **GEM assay**,  
**bypass bottlenecks of hybridoma workflows**

AI-driven multi-parameter screening of **tens of millions** of cells in **hours instead of weeks**


Technologies enable **screening against difficult targets**:  
GPCRs, ion channels and surface antigens

# Screening Technology: GEM Assay


GEL ENCAPSULATED MICROENVIRONMENT



Dual bead GEM




Cell-based GEM




# Screening Technology: xPloration®

## 1 | Loading




Unique through-hole format  
Workflows for OmniAb B-cells

## 2 | Assay + Machine Vision




AI-driven hit detection

## 3 | Recovery & Single-Cell NGS





Precise laser-based recovery  
1 cell/sec (single-cell mode), single-cell barcoding




# Deeper Characterization Identifies New Clonotype Families

Each dot represents an antibody








- **xPloration®** expands on majority of clonotypes identified by GEM assay
- Multiple new clonotype families identified
- Next-generation sequencing (NGS) adds support to new clusters and reveals even more diversity



# The OmniAb Platform

OmniAb Technologies

Create Diverse Antibody Repertoires	Screen Antibody Candidates	Identify the Right Antibody
<p>Create Diverse Pools of High-Quality Naturally Optimized Antibodies</p>  <p>Computational Antigen Design &amp; Proprietary Reagents</p> <p>OmniRat<sup>®</sup> OmniChicken<sup>®</sup> OmniMouse<sup>®</sup></p> <p>Robust Antibodies for Any Target</p> <p>OmniFlic<sup>®</sup> OmniClic<sup>®</sup> OmniTaur<sup>®</sup></p> <p>Bispecific Antibody Generation Cow-inspired Antibodies for Difficult Targets</p>	<p>Screen Millions of Cells to Find Potential Therapeutic Candidates</p>  <p>xPloration High-Throughput Single Cell Screening</p>  <p>Gel Encapsulated Microenvironment (GEM) Single Cell Screening</p>	<p>Further Characterize, Select &amp; Optimize the Right Antibody</p> <ul style="list-style-type: none"> <li>Custom Bioinformatics</li> <li>Next Generation Sequencing (NGS) Hit Expansion</li> <li>Comprehensive Functional Characterization</li> <li>Proprietary Ion Channel Assays</li> </ul>  

Technology offering addresses the most critical challenges of antibody discovery